{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:19:44Z","timestamp":1791094784612,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:02:34Z","timestamp":1773889354000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Suhas","family":"Penukonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyan","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ucl.2026.02.006_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.006_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.eururo.2011.05.047","article-title":"Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden","volume":"60","author":"Akre","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.006_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib5","first-page":"288","article-title":"Biochemical recurrence prediction in high-risk prostate cancer patients, following robot-assisted radical prostatectomy","volume":"59","author":"Yamaguchi","year":"2016","journal-title":"Yonago Acta Med"},{"issue":"21","key":"10.1016\/j.ucl.2026.02.006_bib6","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.006_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.006_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17512433.2018.1429265","article-title":"Neoadjuvant and adjuvant treatment in high-risk prostate cancer","volume":"11","author":"Bandini","year":"2018","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"26","key":"10.1016\/j.ucl.2026.02.006_bib11","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.006_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.006_bib13","first-page":"303","article-title":"Neoadjuvant androgen deprivation therapy effects on perioperative outcomes prior to radical prostatectomy: eleven years of experiences at ramathibodi Hospital","volume":"13","author":"Sangkum","year":"2021","journal-title":"Res Rep Urol"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.006_bib14","doi-asserted-by":"crossref","first-page":"8668","DOI":"10.3390\/curroncol29110683","article-title":"Clinical analysis of perioperative outcomes on neoadjuvant hormone therapy before laparoscopic and robot-assisted surgery for localized high-risk prostate cancer in a Chinese cohort","volume":"29","author":"Sun","year":"2022","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/diseases13040092","article-title":"Neoadjuvant chemohormonal therapy versus pelvic lymphadenectomy on biochemical recurrence in patients with High- or very-high-risk prostate cancer undergoing robot-assisted radical prostatectomy","volume":"13","author":"Kawase","year":"2025","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.006_bib16","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/j.clgc.2023.06.001","article-title":"Novel approaches in the systemic management of high-risk prostate cancer","volume":"21","author":"G\u00f3mez-Aparicio","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.006_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","article-title":"Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"98","author":"Stephenson","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.006_bib18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.eururo.2018.01.012","article-title":"Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian prostate cancer group 12 trial","volume":"73","author":"Ahlgren","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.006_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2019.12.020","article-title":"Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study","volume":"77","author":"Lin","year":"2020","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.ucl.2026.02.006_bib20","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1002\/cncr.28270","article-title":"Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials","volume":"119","author":"Schweizer","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ucl.2026.02.006_bib21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2017.76.4126","article-title":"Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10260","key":"10.1016\/j.ucl.2026.02.006_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.006_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.006_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.ucl.2026.02.006_bib25","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.006_bib26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.006_bib28","first-page":"246","article-title":"Trumps. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"164","author":"Messing","year":"2000","journal-title":"J Urol"},{"issue":"32","key":"10.1016\/j.ucl.2026.02.006_bib29","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/01.JU.0000577260.12278.1c","article-title":"Re: apalutamide for metastatic, castration-sensitive prostate cancer","volume":"202","author":"Chi","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.006_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.006_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004163","article-title":"Apalutamide for high-risk localized prostate cancer following radical prostatectomy (Apa-RP)","volume":"212","author":"Shore","year":"2024","journal-title":"J Urol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.02.006_bib34","doi-asserted-by":"crossref","first-page":"TPS5087","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5087","article-title":"ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","volume":"34","author":"Sandler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.02.006_bib35","doi-asserted-by":"crossref","first-page":"TPS5100","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5100","volume":"37","author":"Taplin","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:20:52Z","timestamp":1776446452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000066"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}